193 related articles for article (PubMed ID: 7457287)
1. Transfer factor: specific and nonspecific effects and chemical characteristics of dialyzable leukocyte lysates (DLL). Part II. Reconstituting effects dialyzable leukocyte lysates. (Second of three parts).
Schindler TE; Baram P
Allergol Immunopathol (Madr); 1980; 8(2):125-9. PubMed ID: 7457287
[No Abstract] [Full Text] [Related]
2. Transfer factor: specific and nonspecific effects and chemical characteristics of dialyzable leukocyte lysates (DLL). Part III. Biochemical characterization. (third of three parts).
Ablin RJ
Allergol Immunopathol (Madr); 1980; 8(3):203-12. PubMed ID: 7405767
[No Abstract] [Full Text] [Related]
3. Transfer factor: specific and nonspecific effects and chemical characteristics of dialyzable leukocyte lysates (DLL). Part I. Introduction. (first of three parts).
Ablin RJ
Allergol Immunopathol (Madr); 1980; 8(1):53-60. PubMed ID: 6996464
[No Abstract] [Full Text] [Related]
4. Immunotherapy with dialyzable leukocyte extracts and studies of their antigen-specific (transfer factor) activity.
Fudenberg HH; Wilson GB; Smith CL
Proc Virchow Pirquet Med Soc; 1980 Dec; 34():3-87. PubMed ID: 6270691
[No Abstract] [Full Text] [Related]
5. Transfer factor II: results of therapy.
Spitler LE; Levin AS; Fudenberg HH
Birth Defects Orig Artic Ser; 1975; 11(1):449-56. PubMed ID: 1096990
[TBL] [Abstract][Full Text] [Related]
6. Transfer factor therapy in immunodeficiency.
Griscelli C
Birth Defects Orig Artic Ser; 1975; 11(1):462-4. PubMed ID: 1148388
[No Abstract] [Full Text] [Related]
7. ["Transfer factor". Experimental findings and prospects for its clinical use].
Medunitsyn NV
Patol Fiziol Eksp Ter; 1977; (1):75-80. PubMed ID: 325478
[No Abstract] [Full Text] [Related]
8. Distinct components in dialyzable leukocyte extracts (DLE) have specific and nonspecific effects on cellular immunity as shown by leukocyte migration inhibition.
Wilson GB; Fudenberg HH; Bahm VJ
Trans Assoc Am Physicians; 1978; 91():295-332. PubMed ID: 754397
[No Abstract] [Full Text] [Related]
9. [Treatment of immunologic deficiency conditions by means of transfer factor].
Kobielowa Z
Pediatr Pol; 1975 Nov; 50(11):1393-7. PubMed ID: 1103073
[No Abstract] [Full Text] [Related]
10. Restoration of cell-mediated immune responses with transfer factor.
Kirkpatrick CH
Birth Defects Orig Artic Ser; 1975; 11(1):441-4. PubMed ID: 1096989
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of monocyte cGMP by leukocyte dialysates. An antigen-independent property of dialyzable transfer factor.
Sandler JA; Smith TK; Manganiello VC; Kirkpatrick CH
J Clin Invest; 1975 Nov; 56(5):1271-9. PubMed ID: 171284
[TBL] [Abstract][Full Text] [Related]
12. In vivo effects of dialyzable leukocyte lysates (DLL): changes in the responses of murine spleen cells to T-and B-cell mitogens, spleen weight, and morphology of splenic tissue.
Huard TK; Sabet T; Baram P
Clin Immunol Immunopathol; 1978 Oct; 11(2):229-44. PubMed ID: 737916
[No Abstract] [Full Text] [Related]
13. Cellular immunity in patients with the Wiskott-Aldrich syndrome before and after administration of transfer factor: a follow-up study.
Schut BJ; Dooren LJ; Uittenbogaart CH; Schellekens PT; Eijsvoogel VP
Immunology; 1979 Jan; 36(1):1-12. PubMed ID: 369991
[TBL] [Abstract][Full Text] [Related]
14. Transfer factor (TFd). Part IV. Transfer factor in mucocutaneous candidiasis treatment.
Miksiewicz-Wasilewska H; Grubek-Jaworska A; Plucińska M; Podsiadło B; Krakówka P; Rzucidło L
Mater Med Pol; 1981; 13(2):108-12. PubMed ID: 7345253
[No Abstract] [Full Text] [Related]
15. The effects of dialyzable products from human leukocyte extracts on cutaneous delayed-hypersensitivity response.
Gottlieb AA; Maziarz GA; Tamaki N; Sutcliffe SB
J Immunol; 1980 Feb; 124(2):885-92. PubMed ID: 7356716
[TBL] [Abstract][Full Text] [Related]
16. [A new approach to immunotherapy: the transfer factor].
Di Padova F
Minerva Med; 1979 May; 70(25):1773-85. PubMed ID: 379697
[TBL] [Abstract][Full Text] [Related]
17. In vitro determination of effects of dialyzable leukocyte extracts containing transfer factor activity.
Schroder I; Rovensky J
Allergol Immunopathol (Madr); 1982; 10(3):171-6. PubMed ID: 7148610
[TBL] [Abstract][Full Text] [Related]
18. Effects of human leukocyte dialysates containing transfer factor in the direct leukocyte migration inhibition (LMI) assay.
Borkowsky W; Lawrence HS
J Immunol; 1979 Oct; 123(4):1741-8. PubMed ID: 479597
[No Abstract] [Full Text] [Related]
19. Effects of therapy with dialyzable leukocyte extracts containing transfer factor activity on antibody-dependent cytotoxic activity in humans.
Nékám K; Láng I; Török K; Kalmár L; Gergely P; Petrányi G
Clin Immunol Immunopathol; 1979 Aug; 13(4):407-12. PubMed ID: 226302
[No Abstract] [Full Text] [Related]
20. [Clinical significance of the transfer factor].
Mutz I; Humphrey GB
Wien Klin Wochenschr; 1973 May; 85(20):357-60. PubMed ID: 4574399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
